Wall Street brokerages expect Neon Therapeutics Inc (NASDAQ:NTGN) to report earnings per share of ($0.62) for the current quarter, according to Zacks. Zero analysts have made estimates for Neon Therapeutics’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.77). Neon Therapeutics posted earnings of ($0.84) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.2%. The business is expected to announce its next earnings report on Monday, March 9th.
On average, analysts expect that Neon Therapeutics will report full year earnings of ($2.55) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($1.71). For the next year, analysts expect that the firm will report earnings of ($2.21) per share, with EPS estimates ranging from ($3.86) to ($1.13). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04).
A number of brokerages have recently weighed in on NTGN. Zacks Investment Research raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Saturday, October 12th. Bank of America lowered shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Neon Therapeutics in a research note on Monday, November 11th. ValuEngine raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird began coverage on shares of Neon Therapeutics in a research note on Thursday, July 25th. They issued an “outperform” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.00.
Several large investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new stake in Neon Therapeutics during the first quarter valued at approximately $49,000. Bank of New York Mellon Corp lifted its stake in Neon Therapeutics by 112.1% during the second quarter. Bank of New York Mellon Corp now owns 71,443 shares of the company’s stock valued at $339,000 after purchasing an additional 37,755 shares during the last quarter. Northern Trust Corp lifted its stake in Neon Therapeutics by 8.5% during the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after purchasing an additional 12,971 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in Neon Therapeutics during the second quarter valued at approximately $149,000. Finally, BlackRock Inc. lifted its stake in Neon Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock valued at $3,631,000 after purchasing an additional 79,729 shares during the last quarter. 67.91% of the stock is owned by institutional investors.
NTGN stock traded down $0.15 during trading on Monday, reaching $1.50. The stock had a trading volume of 141,800 shares, compared to its average volume of 121,770. Neon Therapeutics has a 1-year low of $1.47 and a 1-year high of $7.51. The company has a current ratio of 4.59, a quick ratio of 6.13 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $46.76 million, a P/E ratio of -0.27 and a beta of 1.59. The firm has a fifty day moving average price of $1.95 and a 200 day moving average price of $3.50.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
See Also: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.